
Measuring Tremor Between Visits: What Sine Health's Smartphone Clearance Does and Does Not Prove for Essential Tremor Care
Dr. Dereck Mush, MD, MBACentral nervous system precision neuroscience biopharmaceutical company.
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company based in Boston, Massachusetts, listed on Nasdaq under PRAX. Marcio Souza is president and chief executive officer. Its ulixacaltamide is a selective T-type calcium channel inhibitor. On April 14, 2026, the FDA accepted for review the company's New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults. The application is supported by the Essential3 Phase 3 program, with a PDUFA target action date of January 29, 2027 and no advisory committee meeting expected.
President and chief executive officer
How Praxis Precision Medicines got here, step by step.
December 2025
Ulixacaltamide received FDA Breakthrough Therapy Designation.
14 April 2026
The FDA accepted the New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults, supported by the Essential3 Phase 3 program. The PDUFA target action date is January 29, 2027, with no advisory committee meeting expected.

Dr. Dereck Mush, MD, MBAMentions Praxis Precision Medicines
Related companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: